Radiopharm Theranostics has reported interim results from a Phase 2b study of its imaging agent RAD101 in patients with suspected recurrent brain metastases after radiotherapy. The PET scans agreed with contrast-enhanced MRI in 93.5 per cent of patients.
The data were presented at the 31st annual meeting of the Society for Neuro-Oncology, held in Philadelphia from 12 to 15 November. The company told investors that the results support moving the agent toward a pivotal trial in the United States.
The open-label, single-dose, single-arm study ran across multiple centres. It enrolled 32 participants with suspected recurrence of brain metastases that had already been treated with radiation. The primary endpoint was concordance with MRI. Patient-level agreement between 18F RAD101 PET/CT and contrast-enhanced MRI was 93.5 per cent for detection of all lesions.
Sensitivity was a secondary endpoint and was measured against a reference standard of histopathology or longitudinal MRI follow up. At the interim analysis, it was 85.7 per cent. That figure is based on the 16 participants who could be evaluated against the reference standard at that point. Specificity has not yet been reported. The company expects to release final analyses, including specificity and complete diagnostic performance on follow-up, in the first quarter of 2027.
No serious treatment-emergent adverse events were recorded among the 32 participants dosed. No clinically significant laboratory or ECG abnormalities were also observed.
Chief executive and managing director Riccardo Canevari said the company was pleased to present the findings to clinicians who deal directly with the diagnostic problem.
"We were honoured to present these encouraging interim Phase 2b results at SNO before an audience of neuro-oncology experts who confront the challenge of distinguishing recurrent disease from treatment-related effects on a daily basis," he said.
"For clinicians caring for patients with brain metastases, uncertainty in imaging can have profound implications for treatment decisions, making the need for more accurate diagnostic tools increasingly urgent. We believe the high concordance observed between RAD101 PET/CT and MRI, together with encouraging preliminary sensitivity data and a favourable safety profile, further supports RAD101's potential to address this critical unmet need."
Mr Canevari said Radiopharm recently reached agreement with the US Food and Drug Administration on a pivotal Phase 3 imaging study. The planned trial is a single multicentre study in patients with indeterminate brain metastases after radiotherapy.
"Following our recent alignment with the U.S. FDA on a pivotal Phase 3 imaging study, we remain focused on advancing RAD101 toward a prospective regulatory submission and are actively engaging with potential strategic partners. We look forward to reporting additional diagnostics accuracy analyses as we continue to build the evidence supporting RAD101's differentiated value."
The FDA has granted RAD101 Fast Track designation for distinguishing recurrent disease from treatment effect in brain metastases from solid tumours of different origins, including leptomeningeal disease. Radiopharm has also partnered with Siemens Healthineers, which will manufacture and distribute doses of the radiolabelled agent for the US registrational trial.
RAD101 is a fatty acid analogue labelled with fluorine-18. It images fatty acid metabolism linked to fatty acid synthase, an enzyme that is overexpressed in brain metastases from solid tumours. The company says targeting this activity may allow cancer cells in the central nervous system to be detected more accurately.
The agent was earlier tested in a Phase 2a trial at Imperial College London in patients with brain metastases. Some of those patients had been pretreated with stereotactic radiosurgery, and some had not been treated. According to the company, that trial showed significant tumour uptake regardless of where the tumour originated. It also suggested PET MRI may offer a non-invasive way to predict overall survival, a finding the company says warrants larger studies.
The company says more than 300,000 people are diagnosed with brain metastases each year in the United States alone. It says incidence is rising, partly because better systemic therapies are controlling tumours outside the central nervous system for longer.